Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Liabilities (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Total Liabilities for 6 consecutive years, with $19.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 27.36% year-over-year to $19.2 million, compared with a TTM value of $19.2 million through Sep 2025, down 27.36%, and an annual FY2024 reading of $23.9 million, down 57.42% over the prior year.
  • Total Liabilities was $19.2 million for Q3 2025 at Ovid Therapeutics, down from $21.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $56.2 million in Q4 2023 and bottomed at $10.1 million in Q3 2021.
  • Average Total Liabilities over 5 years is $24.9 million, with a median of $23.0 million recorded in 2022.
  • The sharpest move saw Total Liabilities tumbled 64.0% in 2021, then soared 144.55% in 2023.
  • Year by year, Total Liabilities stood at $14.8 million in 2021, then soared by 55.38% to $23.0 million in 2022, then skyrocketed by 144.55% to $56.2 million in 2023, then plummeted by 57.42% to $23.9 million in 2024, then decreased by 20.01% to $19.2 million in 2025.
  • Business Quant data shows Total Liabilities for OVID at $19.2 million in Q3 2025, $21.6 million in Q2 2025, and $22.4 million in Q1 2025.